UK Medicines Information
Dolutegravir (Tivicay®) 50 mg film-coated tablets
Information type:
Drug best practice guidance
Source:
All Wales Medicines Strategy Group
Specialities:
Infection and infectious diseases
Summary
Dolutegravir (Tivicay®), in combination with other antiretrovirals, is recommended as an option for use within NHS Wales for the treatment of HIV infected adults and adolescents above 12 years of age, as long as the approved Patient Access Scheme is utilised.
UKMi comment
The appraisal report and clinical expert summary are available via the links below.
Related links:
Secretariat Appraisal Report
Clinical Expert Summary